FDA Office That Guided PDUFA V Gets New Name Highlighting Its Strategic Role
This article was originally published in The Pink Sheet Daily
Center for Drug Evaluation and Research’s Office of Planning and Informatics has been renamed the Office of Strategic Programs and is playing a major role in implementing FDA’s patient-focused drug development initiative.
You may also be interested in...
Short public meeting on the biosimilar user fee agreement suggests the proof will be in the scheduling.
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
US FDA final guidance describes possible study design to test whether selected names may misbrand a drug. Agency also okays use of two-letter USAN stems in product names and clarifies use of modifiers.